Ophthalmology

Experts discuss the management of subretinal fluid (SRF) and intraretinal fluid (IRF) in patients with neovascular age-related macular degeneration (nAMD).

From a novel acne cream to a breakthrough depression drug, a half-dozen agent decisions are coming through in the coming 6 months.

However, the presence of diabetic retinopathy was observed to have no significant impact on physical health and quality of life compared to subjects without retinopathy.

After adjusting for potential confounding factors, patients with microvascular diseases, particularly diabetic retinopathy, and diabetic kidney disease, were found to have a greater possibility of left ventricular hypertrophy.

Diabetic retinopathy and microalbuminuria were associated with a significantly higher risk of hemodialysis induction in individuals with T2D.

An analysis of 3 academic health centers suggests youth with diabetic retinopathy had a longer duration of diabetes and higher hemoglobin A1c at the time of the diabetic eye exam.

A new analysis presented at ADA 2023 recommended effective diabetic retinopathy screening for patients with T2D and hypertension.

Veeral Sheth, MD, MBA, FASRS, FACS, offers clinical advice on marking disease progression in neovascular age-related macular degeneration (nAMD).

Experts offer their clinical experience and advice for applying a treat and extend strategy with anti-vascular endothelial growth factor (Anti-VEGF) injections.

A direct comparison of 3 independent AI systems showed differing prevalences of diabetic retinopathy, suggesting inconsistencies when applying these tools to those without preexisting diabetes.

The analysis, from ADA 2023, additionally indicated SGLT2 inhibition showed no effect on the risk of requiring intravitreal injection treatment for DME.

Use of metformin was associated with significant reductions in the risk of developing POAG beyond glycemic control, according to an analysis presented at ADA 2023.

The letter makes reference to an ongoing review of inspection findings from a third-party filler involved with the drug development. Regeneron will not require additional trial data.

APX3330 showed statistically significant prevention of ≥3-step binocular DRSS worsening compared to placebo, but did not meet the study's primary endpoint.

A 7-year longitudinal analysis presented at ADA 2023 suggests time in range was associated with an increased risk of diabetic retinopathy in people with type 1 diabetes.

An analysis presented at ADA 2023 suggests autonomous artificial intelligence testing for diabetic eye diseases promoted health equity across various patient subgroups.

Results from the EMPRISE study presented at ADA 2023 showed empagliflozin was associated with a 23% reduction in the risk of diabetic retinopathy progression in adults with T2D.

An analysis at ADA 2023 presents novel findings on the inverse association between clinical and biochemical factors in diabetic retinopathy and age-related macular degeneration.

A new analysis from ADA 2023 suggests positive discordance according to GMI/A1c ratios was associated with an increased risk for diabetic retinopathy.

According to new data presented at ADA 2023, patients with T2D experience an increased risk of incident retinopathy per 1-SD increase in glycemia risk index.

A new analysis presented at ADA 2023 suggests a machine learning algorithm may refine the risk of diabetic retinopathy progression and personalize screening intervals for patients.

Research presented at ADA 2023 suggests early glycemic screening in high-risk children may predict future diabetes-related complications, including retinopathy and nephropathy.

Experts discuss safety data of anti-vascular endothelial growth factor (Anti-VEGF) agents while highlighting the importance of sharing this information with patients and relevant care providers.

Experts discuss strategies for educating patients, fellows, and shared-care providers on therapies and prospective outcomes for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).

An analysis provided updated estimates of the US prevalence of DR and VTDR, showing that 9.6 million people had DR and 1.84 million people had VTDR in 2021.

The analysis of the DRCR Retina Network Protocol AC suggested cost savings occur with bevacizumab-first step therapy in eyes with DME, but the magnitude might not be as great as previously understood.

Additional phase 4 trial results presented at ENDO 2023 reinforce the efficacy and safety of teprotumumab-trbw in eyes with TED, regardless of disease activity or duration.

Experts discuss barriers that prevent optimal outcomes for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).

Experts provide an overview of anti-vascular endothelial growth factor (Anti-VEGF) treatment for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).

Intravitreal corticosteroid injections improved vision in eyes with persistent or recurrent uveitis-related macular edema better than methotrexate or ranibizumab injections.